The Gist
News and Features
Global Philippines Fine Living
Insights
INVESTMENT STRATEGY
Economy Stocks Bonds Currencies
Webinars
retirement-ss-3
Investor Series: An Introduction to Estate Planning
September 1, 2023
webinar-thumb-1108
Estate Planning: Building a Legacy for the Future 
November 8, 2022
Webinar-mobile-desktop-267x320-1
Outlook 2022: Recover. Restart. Rebalance.
March 31, 2022
View All Webinars
Downloads
bonds-ss-7
Economic Updates
Policy Rate Updates (September 21, 2023)  
DOWNLOAD
makait-city-building-economy
Economic Updates
Economic Updates (September 15, 2023)
DOWNLOAD
stock-market-as
Consensus Pricing
Consensus Pricing – September 12, 2023
DOWNLOAD
View all Reports
Metrobank.com.ph Contact Us
Follow us on our platforms.

How may we help you?

TOP SEARCHES
TRENDING ARTICLES

Login

Access Exclusive Content
Login to Wealth Manager
Economy 1 MIN READ

BRIEF-Shanghai Henlius Biotech Announces License Agreement With Getz Pharma For Rights Of Handayuan

February 23, 2022By Reuters
Related Articles
Markets lose steam, central banks not helping June 20, 2023 China manufacturing PMI, Aussie GDP top data deluge February 28, 2023 Oil prices surge around 1% on optimism over China's recovery January 18, 2023

Feb 23 (Reuters) – Shanghai Henlius Biotech Inc 2696.HK:

  • ANNOUNCES LICENSE AGREEMENT WITH GETZ PHARMA FOR RIGHTS OF HANDAYUAN

  • TO GRANT LICENSE TO GETZ PHARMA TO COMMERCIALISE ADALIMUMAB INJECTION IN PAKISTAN, PHILIPPINES, AMONG OTHER COUNTRIES

Further company coverage: 2696.HK

((Reuters.Briefs@thomsonreuters.com;))

This article originally appeared on reuters.com

Read More Articles About:
Worldwide News Philippine News Rates & Bonds Equities Economy Investment Tips Fine Living